Atlas Genetics Appoints Life Sciences Veteran, Jeffrey Luber, as Chief Executive Officer; Founding CEO Dr John Clarkson Steps Up to Executive Chairman

03 October 2017

Expanded Board and Blue Chip Investors Position Company for Global Reach

BATH, England, October 3, 2017 - Atlas Genetics Ltd., the ultra-rapid, point-of-care (POC) testing company for women's and family health, today announced that Jeffrey R. Luber has been appointed Chief Executive Officer effective 1 October 2017. Dr John Clarkson, current founding CEO, will become Executive Chairman and current chairman, Neil Butler, will remain with the Company as a non-executive director of the Board.

Mr. Luber joins the Board of Atlas Genetics with broad experience in the life sciences industry, including having held multiple leadership roles in both public and private companies. Most recently, he led the return to growth and sale of Good Start Genetics to Invitae Corp (NYSE: NVTA). In this role, Jeff led the company in new directions, restoring growth to its core business, expanding its reach into consumer markets, and entering into transformative strategic partnerships with Roche Diagnostics and Amazon. Prior to this, Jeff was CEO of EXACT Sciences (NASDAQ: EXAS) where he executed its successful turnaround and strategic transaction with Genzyme Corp.

Dr John Clarkson, founding CEO of Atlas Genetics, said: "We are delighted to welcome Jeff to Atlas Genetics. Jeff's proven track record and extensive experience in the commercialisation of in vitro diagnostics will be invaluable as we enter the next, exciting phase of growth aimed at improving the diagnosis and treatment of conditions affecting women and families."    

Mr Jeffrey Luber, commented:  "I am thrilled to join Atlas Genetics, given the power of its platform, the strength of its board and leadership team, andits experienced investor syndicate. Dr. Clarkson has built a world class team of scientists and engineers who havedeveloped a truly differentiating technology platform in Point of Care testing for broad global markets. As diagnostic testing increasingly becomes more decentralized, I look forward to working with the team to make Atlas the leadingglobal player in POC testing." 

Florent Gros, Managing Director of Novartis Venture Fund and non-executive director of Atlas Genetics, added: "At Novartis Venture Fund, we seek out novel platforms to address global unmet needs and stellar management to drive innovation and growth. With Point of Care testing expected to grow to 35% by 2020, from less than 1% today, we are thrilled to have Jeff on board and look forward to his leadership through this very exciting next phase of global growth for the company."  

Atlas Genetics' Investors include Novartis Venture Fund, Johnson & Johnson Innovation - JJDC, Inc., Consort Medical plc and China-based Wondfo Biotech.

About Atlas Genetics 

Atlas Genetics is an in vitro diagnostics company focused on decentralized, near-patient and point-of-care (POC) testing for the benefit of women and families globally. The Company's proprietary technology platform is positioned to improve patient outcomes by arming healthcare professionals with a simple-to-use, rapid and cost-effective solution for on-demand diagnosis of infectious diseases. Rapid turnaround times, high accuracy and low cost are hallmarks of the company's broad platform for a broad range of infectious diseases. The io® platform offers a sample-to-answer time of 30 minutes, or less, making it possible to carry out infectious disease tests in primary care clinics and physicians' offices anywhere.


Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin

Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares